|
|
Rituximab
Links to news articles on
Rituximab
.
Novel therapy for chronic graft-versus-host disease (GVHD) using ... -- Mar 27, 2006
Dana-Farber researchers found that rituximab reduced the severity of chronic graft ... A study by Dana-Farber Cancer Institute researchers offers the strongest ... News-Medical.net,
Point Therapeutics to Present at CIBC World Markets Annual ... -- Mar 29, 2006
...melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in metastatic pancreatic cancer. ... Genetic Engineering News,
Rituximab Effective in Treating Chronic Graft-Versus-Host Disease -- Mar 23, 2006
Newswise — A study by Dana-Farber Cancer Institute researchers offers the strongest evidence ... The use of the therapy, a drug known as rituximab, grew out of ... Newswise (press release)
Rituximab effective in treating chronic graft-versus-host disease -- Mar 24, 2006
By Dana-Farber Cancer Institute, A study by Dana-Farber Cancer Institute researchers offers the ... The use of the therapy, a drug known as rituximab, grew out of ... RxPG NEWS,
Rituxan Promising for Chronic Graft-versus-Host Disease -- Mar 24, 2006
For refractory chronic graft-versus-host disease (GvHD), Rituxan (rituximab) may offer ... reported Corey Cutler, MD, MPH, of the Dana-Farber Cancer Institute here ... MedPage Today,
Lymphoma Drug Effective Against Chronic GVHD -- Mar 24, 2006
March 24, 2006 ) – More research points to the benefit of using the drug rituximab to combat chronic graft-versus-host disease (GVHD) in cancer patients who ... Cancerpage.com,
Algeta Demonstrates Radioimmunotherapeutic Potential of a Tumor ... -- Mar 23, 2006
...with alpha-emitting radionuclides for the targeting and treatment of cancer. ... a Thorium-227 conjugate of the chimeric mAb rituximab retains immunoreactivity ... Market Wire (press release)
TRACON Pharmaceuticals Assembles Industry-Leading Management Team ... -- Mar 15, 2006
...former co- chair of the Southwest Oncology Group (Lung Cancer Committee), Dr ... regulatory filings that supported the approval of Rituxan® (rituximab) and Zevalin ... Yahoo! News (press release)
New use for cancer drug OK'd -- Mar 1, 2006
Rituxan, known formally as rituximab, is being studied as a treatment for other ... Kantor forecasts Rituxan sales for cancer and arthritis will grow to a total $2 ... Seattle Post Intelligencer
Cancer drug Rituxan receives federal approval to treat rheumatoid ... -- Mar 1, 2006
WASHINGTON - The nation's best-selling cancer drug has won federal approval as a ... Rituxan, known formally as rituximab, is being studied as a treatment for ... San Jose Mercury News,
Cancer drug receives federal approval for rheumatoid arthritis -- Mar 1, 2006
The nation's best-selling cancer drug has won federal approval as a treatment ... Rituxan, known formally as rituximab, is being studied as a treatment for other ... San Francisco Chronicle,
Cancer Drug Approved for Rheumatoid Arthritis -- Mar 1, 2006
...of a widely used cancer drug to treat cases of rheumatoid arthritis that do not respond to other therapies, the drug's makers said. Rituxan (rituximab) targets ... Forbes
Cancer Drug OK‘d As Arthritis Treatment -- Mar 2, 2006
...could achieve billion (dollars-per-year) potential in non-cancer indications," Kantor ... Rituxan, known formally as rituximab, is being studied as a treatment for ... Olberlin,
Cancer drug OK for type of arthritis; other uses studied -- Mar 2, 2006
...analyst said Wednesday that Rituxan's use for diseases other than cancer could make ... Rituxan, known formally as rituximab, is being studied as a treatment for ... Akron Beacon Journal,
Point Therapeutics Reports Fourth Quarter and Year-End 2005 ... -- Mar 14, 2006
...a portion of Point's current Phase 2 study combining talabostat with rituximab in advanced ... two phase 3 trials for metastatic non-small cell lung cancer (NSCLC ... Genetic Engineering News,
Cancer drug Rituxan receives federal approval to treat rheumatoid ... -- Mar 1, 2006
March 1, 2006 - The nation's best-selling cancer drug has won federal approval ... Rituxan, known formally as rituximab, is being studied as a treatment for other ... ABC7Chicago.com,
Cancer drug to remedy arthritis -- Mar 3, 2006
WASHINGTON - The nation's best-selling cancer drug, Rituxan, has won federal approval ... Rituxan, known formally as rituximab, is being studied as a treatment for ... Albuquerque Tribune,
Top Cancer Drug Gets OK For Rheumatoid Arthritis -- Mar 1, 2006
...(AP) The nation's best-selling cancer drug has ... Rituxan, known formally as rituximab, is being studied as a treatment for other autoimmune diseases, including ... CBS 5,
Cell Therapeutics, Inc. (CTI) Reports 2005 Fourth Quarter and Year ... -- Mar 9, 2006
...prolonging time to progression when added to rituximab compared to rituximab alone, in ... survival benefit for women with non-small cell lung cancer on XYOTAX ... MSN Money
Supergen Announces Results from Combination Study in Cll Published ... -- Mar 14, 2006
...the Cleveland Clinic and Memorial Sloan Kettering Cancer Center demonstrated ... drug combination therapy of pentostatin, cyclophosphamide and rituximab (PCR) for ... PharmaLive.com (press release),
Pentostatin, Cyclophosphamide, Rituxan® Active in Chronic ... -- Mar 10, 2006
Cytoxan®), and the biologic agent Rituxan® (rituximab) appears promising for ... The American Cancer Society estimates that approximately 8,000 people will be ... Cancer Consultants (press release),
TeGenero Mab causes shock side-effects in UK trial -- Mar 17, 2006
...and Biogen Idec's leukemia treatment Rituxan/MabThara (rituximab), which achieved $1.8 ... medicines, particularly in chronic disorders such as cancer and multiple ... Pharmaceutical Business Review
RQ-PCR Positivity Predicts Relapse of Mantle Cell Lymphoma after ... -- Mar 9, 2006
...at diagnosis, bone marrow involvement, and lymphoma cancer cells in the ... Many chemotherapy agents, and specifically Rituxan® (rituximab), have shown activity ... Cancer Consultants (press release),
FDA Approves First Rheumatoid Arthritis Ind ication for Rituxan ... -- Mar 1, 2006
...of lymphatic cancer called non-Hodgkin's lymphoma (NHL). About the REFLEX study The REFLEX study (Randomised Evaluation oF Long-term Efficacy of Rituximab in RA ... PharmaLive.com (press release),
FDA Approves First Rheumatoid Arthritis Indication for Rituxan ... -- Mar 1, 2006
...treatment of a form of lymphatic cancer called non-Hodgkin’s lymphoma (NHL). The REFLEX study (Randomised Evaluation oF Long-term Efficacy of Rituximab in RA ... WebWire (press release),
Genentech/Biogen Idec: Rituxan further expands its options -- Mar 2, 2006
This is mainly due to the fact that more than 730,000 patients have already been treated with rituximab worldwide, in its cancer indication. ... Pharmaceutical Business Review
Biovest International Submits Amendment Request To FDA For Use Of ... -- Feb 26, 2006
...basis of BiovaxID and its implications for this otherwise fatal cancer. ... By contrast, Rituxan® (rituximab) a passive immunotherapeutic consisting of a ... Medical News Today (press release),
Midday Business Report: O’Reilly jumps on earnings report -- Mar 1, 2006
The nation’s best-selling cancer drug has won federal approval as a treatment ... Rituxan, known formally as rituximab, is being studied as a treatment for other ... Kansas City Star,
FDA clears Rituxan for rheumatoid arthritis -- Mar 1, 2006
Genentech and Biogen Idec won approval to market their cancer drug Rituxan as ... Rituxan (rituximab) is already a blockbuster drug in its current indication of non ... Pharma Times (subscription),
Genentech, Biogen Idec Gain Approval Of Rituxan In RA -- Mar 1, 2006
...approved Rituxan (rituximab) for rheumatoid arthritis, broadening the therapeutic antibody’s label and potentially its revenue. Long sold as a cancer therapy ... BioWorld Online (subscription),
Sawyer woman continues battle -- Feb 25, 2006
Last fall, she had to stop treatments of Rituximab, a drug originally used to treat cancer, because she couldn’t tolerate the side effects. ... In-Forum (subscription),
Treandaâ„¢ Has Significant Activity in Treatment of Recurrent NHL -- 25 Jan 2006
...s lymphoma in patients who have stopped responding to chemotherapy and/or Rituxan® (rituximab). Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins ... Cancer Consultants (press release),
GlycoFi Announces the First Production of Antibodies with Human ... -- Jan 23, 2006
...to produce a library of glycoforms of the anti-CD20 antibody rituximab and to ... on antibodies we have shown that the antibodies ability to kill cancer cells can ... Genetic Engineering News,
Genetic Features Predict Response of Chronic Lymphocytic Leukemia ... -- Jan 20, 2006
...of Rituxan® (rituximab) and Fludara® (fludarabine). Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia. The American Cancer Society ... Cancer Consultants (press release),
BiovaxID, Personalized Anti-Cancer Vaccine from Biovest ... -- Jan 10, 2006
...centers in the US being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. ... 1)Rituxan (rituximab) is a ... PharmaLive.com (press release),
Point Therapeutics To Host Webcast On January 31, 2006 Webcast To ... -- Jan 20, 2006
...melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in metastatic pancreatic cancer. ... Genetic Engineering News,
Revlimid, as oral treatment regimen in chronic lymphocytic ... -- Jan 19, 2006
...at day 30, and then monthly using the National Cancer Institute-Working ... complete response and those with progressive disease then received Rituximab at ( 375mg ... Xagena.it,
HuMax®-CD20 Safe and Effective Treatment for Relapsed/Refractory ... -- Jan 10, 2006
...anticancer activity in patients with chronic lymphocytic leukemia (CLL) who have stopped responding to Rituxan® (rituximab). CLL is a cancer involving the ... Cancer Consultants (press release),
Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... -- Jan 13, 2006
Researchers from the MD Anderson Cancer Center have reported that the combination of Rituxan® (rituximab) and granulocyte macrophage-colony stimulating factor ... Cancer Consultants (press release),
Genentech's Shares Fall On Disappointing Avastin Sales -- Jan 11, 2006
Rituxan (rituximab) sales led the way with $484.4 million for the three ... Genentech's breast cancer drug, Herceptin (trastuzumab) posted fourth-quarter sales of ... BioWorld Online (subscription),
Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... -- Jan 12, 2006
Researchers from MD Anderson Cancer Center have reported that the combination of Rituxan (rituximab) and granulocyte macrophage-colony stimulating factor ... Cancer Consultants (press release),
ZEVALIN® Radioimmunotherapy May Play Greater Role In Combination ... -- Dec 27, 2005
...in DLBCL Paul A. Hamlin, MD, of Memorial Sloan-Kettering Cancer Center, delivered a ... effectiveness of first line use of ZEVALIN and standard rituximab plus CHOP ... Medical News Today (press release),
Genentech Announces Full Year and Fourth Quarter 2005 Results -- Jan 10, 2006
...success in clinical trial results and FDA filings for potential therapeutics to treat cancer, blindness and ... US sales of Rituxan(R) (Rituximab) in 2005 ... MSN Money
Immunochemotherapy Improves Outcome in Chronic Lymphocytic ... -- Jan 17, 2006
...for 5 days) followed by four weekly doses of rituximab (375 mg/m2). The overall response rate was 93%, the team reports in the December 15th issue of Cancer. ... Cancerpage.com,
Genentech Announces Full Year and Fourth Quarter 2005 Results -- Jan 10, 2006
...success in clinical trial results and FDA filings for potential therapeutics to treat cancer, blindness and ... US sales of Rituxan® (Rituximab) in 2005 ... Yahoo! News (press release)
Addition of Rituxan® to CVP Provides Long-Term Benefits in ... -- Dec 29, 2005
Among patients with follicular lymphoma, the addition of Rituxan® (rituximab) to the CVP ... Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the ... Cancer Consultants (press release),
Genentech's Q4 profit jumps 64%, but shares slip -- Jan 11, 2006
The company's flagship drug, Rituxan (rituximab), which is used to treat non ... new kid on the block, Avastin (bevacizumab), cleared to treat colon cancer by the ... Pharma Times (subscription),
Genentech/Biogen Idec: wearing the drug marketing suit well? -- Jan 12, 2006
To date, Rituxan (rituximab) has only been approved by the FDA for non-Hodgkin's lymphoma, but doctors are already prescribing it for other cancer types. ... Pharmaceutical Business Review
Rituxan® Improves Survival in Patients with Follicular Lymphoma -- Dec 29, 2005
Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced ... Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia ... Cancer Consultants (press release),
Biotech Racks Up Another Impressive Quarter to Close Year in ... -- Jan 3, 2006
...protective chemotherapy agent used to treat late-stage breast cancer; Targretin, a ... results of a Phase III clinical study of Rituxan (Rituximab) in rheumatoid ... PR Newswire (press release),
CVP Plus Rituxan® Provides Long-Term Benefits in Patients with ... -- Dec 29, 2005
A multi-center randomized international trial determined that the addition of Rituxan® (rituximab) to CVP (cyclophosphamide, vincristine, and prednisone ... Cancer Consultants (press release),
Rituxan® Improves Survival in Patients with Follicular Lymphoma -- Dec 30, 2005
Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B have reported that the addition Rituxan (rituximab) to CVP ... Cancer Consultants (press release),
New therapy helps MS patients get on their feet -- Jan 9, 2006
Neurologist Olaf Stuve, MD, Ph.D., says the cancer drug rituximab (Rituxan) is the first treatment to target the B cells in patients with MS, and it could be ... ABC7Chicago.com,
Targeted cancer therapies: Another step forward -- Dec 22, 2005
...by five key products: Genentech/Roches Rituxan (rituximab), Herceptin (trastuzumab ... move into the adjuvant treatment setting for breast cancer, with forecast ... News-Medical.net,
Targeted cancer therapies: another step forward -- Dec 23, 2005
...therapies have brought progress in the treatment of cancer, it would be ... by five key products: Genentech/Roche’s Rituxan (rituximab), Herceptin (trastuzumab ... Pharmaceutical Business Review
Genelabs suffers setback on lupus drug -- Jan 16, 2006
One hope for sufferers of the disorder lies with Genetech/Biogen Idec's cancer drug Rituxan (rituximab), which is already on the market for non-Hodgkin's ... Pharma Times (subscription),
Targeted cancer therapies: Another step forward -- Dec 22, 2005
...mainly by five key products: Genentech/Roche's Rituxan (rituximab), Herceptin (trastuzumab ... into the adjuvant treatment setting for breast cancer, with forecast ... News-Medical.net,
Targeted cancer therapies: another step forward -- 23 Dec 2005
...therapies have brought progress in the treatment of cancer, it would be ... by five key products: Genentech/Roche’s Rituxan (rituximab), Herceptin (trastuzumab ... Pharmaceutical Business Review
Targeted cancer therapies: Another step forward -- Dec 22, 2005
...by five key products: Genentech/Roches Rituxan (rituximab), Herceptin (trastuzumab ... move into the adjuvant treatment setting for breast cancer, with forecast ... News-Medical.net,
Genentech Submits Supplemental Biologics License Application for ... -- Dec 19, 2005
Genentech is committed to changing the way cancer is treated by ... is leading clinical development programs for Rituxan® (Rituximab), Herceptin® (Trastuzumab ... Yahoo! News (press release)
Genentech Submits Supplemental Biologics License Application for ... -- Dec 19, 2005
Genentech is committed to changing the way cancer is treated by establishing a ... is leading clinical development programs for Rituxan(R) (Rituximab), Herceptin(R ... PharmaLive.com (press release),
Rituximab maintenance therapy dramatically improves survival in ... -- Dec 13, 2005
Two years of maintenance therapy with MabThera (rituximab) dramatically improves the ... showed unprecedented survival benefits in a serious cancer disease which ... RxPG NEWS,
Immunomedics Reports Updated Clinical Results of Epratuzmab ... -- Dec 9, 2005
Central Cancer Treatment Group, a national clinical research group sponsored by the NCI, also plans to evaluate epratuzumab in combination with rituximab and ... PR Newswire (press release),
Human Genome Sciences Reports Results of Phase 2 Clinical Trial of ... -- Dec 12, 2005
Cancer Institute (Buffalo, NY), said, "The in vitro data that we presented here at the ASH annual meeting show that the combination of HGS-ETR1 and rituximab ... Yahoo! News (press release)
Studies of Nipent(R) in Combination Cancer Therapies for Treatment ... -- Dec 9, 2005
A combination regimen of pentostatin, cyclophosphamide and rituximab (PCR) is suggested to have comparable activity to fludarabine, cyclophosphamide, and ... PR Newswire (press release),
New Data Demonstrate ZEVALIN(R) Radioimmunotherapy May Play ... -- Dec 13, 2005
Paul A. Hamlin, MD, of Memorial Sloan-Kettering Cancer Center, delivered a poster ... effectiveness of first line use of ZEVALIN and standard rituximab plus CHOP (R ... Genetic Engineering News,
VELCADE(R) (bortezomib) for Injection Continues to Show Impressive ... -- Dec 12, 2005
...standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) plus rituximab for the ... by Steven Treon, MD, Ph.D., of Dana Farber Cancer Institute in ... PR Newswire (press release),
Point Therapeutics Announces Positive Interim Results at American ... -- Dec 12, 2005
...melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in metastatic pancreatic cancer. ... Business Wire (press release),
Rituxan® and CHOP for Elderly Patients with Diffuse Large B-Cell ... -- Dec 19, 2005
Researchers in Germany have reported that six cycles of Rituxan® (rituximab) and CHOP ... Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the ... Cancer Consultants (press release),
Cephalon Oncology Reports High Response Rates to Single Agent ... -- Dec 12, 2005
...not respond to other alkylators and were relapsed from rituximab," commented principal ... Clinical Research at the University of Rochester Wilmot Cancer Center in ... Yahoo! News (press release)
New Data Suggest GM-CSF May Enhance Efficacy of Rituximab in ... -- Dec 12, 2005
...cellular cytotoxicity (ADCC) activity, an immune response that makes cancer cells vulnerable to attack by immune cells, was demonstrated after rituximab/GM-CSF ... PR Newswire (press release),
Pilot Clinical Study of Genasense(R) Plus Rituxan(R) and ... -- Dec 12, 2005
...of treatment, and most patients were able to continue rituximab treatment ... to directly target the biochemical pathway known as apoptosis whereby cancer cells are ... PR Newswire (press release),
Hana Biosciences Announces Changes to Strengthen Management Team -- Dec 16, 2005
Before joining Hana, Vitale led the Rituxan(R) (rituximab) commercial team and ... development, licensing and life cycle management for cancer products including ... Business Wire (press release),
Phase II Study Demonstrates that ONTAK(R) Benefits Patients with ... -- Dec 14, 2005
...lymphoma Ligand plans to launch two new studies of ONTAK plus rituximab in this ... critical unmet medical needs of patients in the areas of cancer, pain, skin ... Business Wire (press release),
Other News To Note -- Dec 9, 2005
...chemotherapy treatment for patients with hormone-refractory prostate cancer, and several ... a European trial of epratuzumab in combination with rituximab to treat ... TMCnet
Ascenta AT-101 Data Presented at the American Society of ... -- Dec 12, 2005
Cancer Center in New York City and The Regina Elena Cancer Institute in ... when AT-101 was added to a regimen of cyclophosphamide and rituximab versus treatment ... PharmaLive.com (press release),
Viragen Holds Annual Stockholder Meeting: CEO Issues Progress ... -- Dec 15, 2005
...evaluation study. The combination led to a significant increase in the destruction of cancer cells as compared to rituximab alone. ... PR Newswire (press release),
Scientific Advances on Three Lead Cephalon Oncology Compounds to ... -- Dec 8, 2005
R) (arsenic trioxide) injection, the company's marketed anti-cancer therapeutic ... from both traditional alkylators and the monoclonal antibody rituximab (Rituxan(R ... PR Newswire (press release),
Maintenance therapy with RITUXAN(R) dramatically improves survival -- Dec 12, 2005
12 /CNW/ - Two years of maintenance therapy with Rituxan (rituximab) dramatically improves the ... on the study and an oncologist with the BC Cancer Agency in ... CNW Telbec (Communiqués de presse),
Maintenance therapy with RITUXAN(R) dramatically improves survival -- Dec 12, 2005
12 /CNW/ - Two years of maintenance therapy with Rituxan (rituximab) dramatically improves the ... initial treatment in an attempt to keep cancer from progressing ... Canada NewsWire (press release),
Pharmacyclics Announces Presentation and Publication of ... -- Dec 12, 2005
RIT) Produces High Complete Remission Rates in Relapsed Rituximab-Refractory Follicular Non ... Pharmacyclics is developing Xcytrin as an anti-cancer agent with a ... PR Newswire (press release),
Scientific Advances on Three Lead Cephalon Oncology Compounds to ... -- Dec 8, 2005
...arsenic trioxide) injection, the company's marketed anti-cancer therapeutic. ... from both traditional alkylators and the monoclonal antibody rituximab (Rituxan ... Yahoo! News (press release)
REVLIMID(R) Clinical Results as Oral Treatment Regimen in Chronic ... -- Dec 12, 2005
Cancer Institute-Working Group criteria. CLL patients with SD or better response continued on therapy until CR and those with PD then received Rituximab at ... Yahoo! News (press release)
ZymoGenetics Announces Presentation of TACI-Ig Phase 1 Preliminary ... -- Dec 12, 2005
...activity of rituximab and provide evidence for evaluating IL-21 and rituximab combination therapy ... is developing IL-21 for the treatment of cancer, initially in ... Yahoo! News (press release)
ASH: Experimental Chemotherapy Drug Effective Against Resistant ... -- Dec 14, 2005
...respond to other alkylators and were relapsed from rituximab," Dr. Friedberg ... refractory NHL, chronic lymphocytic leukemia, multiple myeloma, and breast cancer. ... MedPage Today,
MABTHERA MAINTENANCE THERAPY DRAMATICALLY IMPROVES SURVIVAL FOR ... -- Dec 12, 2005
Two years of maintenance therapy with MabThera (rituximab) dramatically improves the ... European Organisation for Research and Treatment of Cancer) trial, 465 ... ITNews,
Six Cycles of Bi-Weekly R-CHOP Standard for Elderly with Diffuse ... -- Dec 19, 2005
Researchers affiliated with the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL) have reported that 6-cycles of Rituxan® (rituximab) and CHOP ... Cancer Consultants (press release),
Immunomedics Reports Humanized Anti-CD20 Antibody Appears Safe and ... -- Dec 12, 2005
...in vitro and in vivo CD20 binding and efficacy against lymphoma as rituximab. ... antibody-based products for the targeted treatment of cancer, autoimmune and ... PR Newswire (press release),
Chemotherapy Consolidation with Zevalin(R) (90Y-Ibritumomab ... -- Dec 12, 2005
...penetrate the tumor from several angles and creates a potent cancer-cell destroying ... for Zevalin for the treatment of adult patients with rituximab relapsed or ... PR Newswire UK (press release),
Rituxan® is an Effective for “Purging� of Stem Cell Grafts ... -- Dec 15, 2005
Researchers from Case Western Reserve and Cancer Center have reported that in-vivo purging with Rituxan® (rituximab) is effective as or more effective than ex ... Cancer Consultants (press release),
MDS Nordion Supports GlaxoSmithKline Inc. in Providing Innovative ... -- Nov 24, 2005
...latest in a new generation of patient-tailored cancer treatments that ... grade, follicular, or transformed NHL, including patients with rituximab-refractory NHL. ... PR Newswire (press release),
Favrille Reports Positive Data from Phase 2 Clinical Trial of ... -- Dec 13, 2005
...patient-specific immunotherapies for the treatment of cancer, reported positive long ... of Patients Receiving FavId (Id/KLH) Vaccine Following Rituximab," Omer Koc ... PR Newswire (press release),
Annual Meeting of the American Society of Hematology Highlights ... -- Dec 6, 2005
...with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia ... Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously ... PR Newswire (press release),
Genta study sees Genasense combo benefit -- Dec 12, 2005
...preliminary clinical results from two studies show its cancer treatment Genasense ... Genasense and fludarabine when used with the antibody rituximab in patients ... BusinessWeek
R-CHOP Improves Outcomes as Initial Therapy in Follicular Lymphoma -- Nov 28, 2005
...a recent article published in the journal Blood, the addition of Rituxan® (rituximab) to the ... Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in ... Cancer Consultants (press release),
Pharmacyclics Announces Presentation and Published Abstracts on ... -- Dec 6, 2005
Balance Abstract #4829 Title: Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity ... Pharmacyclics is developing Xcytrin as an anti-cancer agent with a ... PR Newswire (press release),
Biogen Idec kondigt aftreden aan van William H. Rastetter als ... -- Dec 7, 2005
Bill Rastetter's drive and unyielding commitment to those we serve that resulted in bringing RITUXAN(R) (rituximab), the world's leading cancer therapeutic, to ... Netherlands Corporate News,
Pharmacyclics Announces Presentation and Published Abstracts on ... -- Dec 6, 2005
Remission Rates in Relapsed Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma (NHL). Pharmacyclics is developing Xcytrin as an anti-cancer agent with a ... PharmaLive.com (press release),
Genmab Announces Data on All Evaluable Patients in HuMax(R)-CD20 ... -- Dec 1, 2005
...a median of 2 treatment regimens, including the possibility of rituximab. ... Genmab has numerous products in development to treat cancer, infectious disease ... PR Newswire (press release),
Nipent®/Cytoxan®/Rituxan® Shows High Activity in High-Risk ... -- Nov 23, 2005
Clinical have reported that the treatment combination consisting of Nipent (pentostatin), Cytoxan (cyclophosphamide) and Rituxan (rituximab) demonstrates high ... Cancer Consultants (press release),
New Data on VELCADE(R) (bortezomib) for Injection to Be Presented ... -- Dec 6, 2005
...non-Hodgkin's lymphoma (abstract #7) -- Combination with CHOP plus rituximab in B-cell ... based in Cambridge, Mass., markets VELCADE, a novel cancer product, and ... PR Newswire (press release),
BioCryst Out-Licenses BCX-4208 To Roche In Potential $560M Deal -- Nov 30, 2005
...as well as a recent study that showed that Rituxan (rituximab) is good for ... Beyond cancer, the company's portfolio has gained recent attention for its antiviral ... BioWorld Online (subscription),
Rehaumatoid arthritis - MabThera provides lasting benefits -- 21 Nov 2005
...a strong heritage in the treatment of a form of lymphatic cancer called non ... REFLEX (Randomised Evaluation oF Long-term Efficacy of RituXimab in RA) is a pivotal ... Medical News Today (press release),
Cancer drug helps arthritis -- study -- Nov 14, 2005
...and Biogen Idec Inc.'s cancer drug Rituxan improved symptoms of rheumatoid arthritis in patients not helped ... "For those patients, adding rituximab (Rituxan) to ... ABC News
Pentostatin/Cytoxan®/Rituxan® Shows High Activity in High-Risk ... -- Nov 17, 2005
Cytoxan® (cyclophosphamide) and the monoclonal antibody Rituxan® (rituximab) produces impressive ... CLL is a cancer involving the lymph (immune) system, which ... Cancer Consultants (press release),
Genasense(R) Enhances Preclinical Activity of Tarceva Using an ... -- Nov 15, 2005
...dose anticancer therapies, such as temozolomide and interferon in melanoma, rituximab in lymphoma, tyrosine kinase inhibitors in lung cancer, and radiation ... PR Newswire (press release),
Point Therapeutics Announces Positive Results at AACR-EORTC-NCI ... -- Nov 16, 2005
...melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in metastatic pancreatic cancer. ... Genetic Engineering News,
INEX to Spin Off Targeted Immunotherapy Assets -- Nov 17, 2005
...and breast cancer models. Data presented in a preclinical model of lymphoma demonstrated that treatment with the monoclonal antibody rituximab (Rituxan(R ... PR Newswire (press release),
Favrille Announces New Data From Phase 2 Clinical Trial of FavId ... -- Nov 15, 2005
...developing patient-specific immunotherapies for the treatment of cancer, announced today ... Patients Receiving FavId (Id/KLH) Vaccine Following Rituximab," is now ... PR Newswire (press release),
Genentech/Biogen cancer drug granted priority review by FDA -- Oct 27, 2005
27 Oct 2005, 09:37 GMT - The application applies to the use of Rituxan (rituximab) in previously-untreated ... Non-Hodgkins lymphoma a cancer of the lymph system. ... Pharmaceutical Business Review
FDA Grants Priority Review for Rituxan (Rituximab) Supplemental ... -- Oct 25, 2005
Application (sBLA) submitted by the companies for Rituxan(R) (rituximab) in previously ... According to the American Cancer Society, more than 56,000 men and women ... DG News
Positive Results of Phase III Study of Rituxan in Rheumatoid ... -- Nov 16, 2005
...of a Phase III clinical study of Rituxan(R) (Rituximab) in rheumatoid ... leader in diagnostics, the leading supplier of medicines for cancer and transplantation ... PharmaLive.com (press release),
*vwd/BUSINESS WIRE: Positive Ergebnisse der Testphase III zu " ... -- Nov 16, 2005
...der klinischen Testphase III zu Rituxan(R) (Rituximab) gegen rheumatische ... in diagnostics, the leading supplier of medicines for cancer and transplantation and ... Vereinigte Wirtschaftsdienste,
Disease Modification in Rheumatoid Arthritis - Pipeline Uptake ... -- Nov 17, 2005
...between the next DMARDs to be launched, Rituxan/MabThera (rituximab) and Orencia (abatacept). Rituximabs promising dosing and use in cancer indications gives ... Business Wire (press release),
Multimedia News Release -- FDA Approves Tarceva(R) in Combination ... -- Nov 3, 2005
BioOncology Genentech is committed to changing the way cancer is treated by ... is leading clinical development programs for Rituxan(R) (Rituximab), Herceptin(R ... PR Newswire (press release),
Treatment Advances For Lymphoma Have Reduced Deaths By 70% -- Oct 20, 2005
The Wilmot Cancer Center has established one of the Northeast's largest hematologic ... comparing the two most effective therapies: CHOP plus rituximab and CHOP ... Science Daily (press release)
30 years of advances in lymphoma have slashed deaths -- Oct 22, 2005
Research Center in Seattle and University of Arizona Cancer Center assessed ... and prednisone, called CHOP, plus new monoclonal antibodies (rituximab or iodine ... Cancerfacts.com,
Is it a bus? Is it a coach? No, it's a tram on wheels -- Nov 4, 2005
...reviewed using the rapid process will be docetaxel (Taxotere), paclitaxel (Taxol) and trastuzumab (Herceptin), all for breast cancer, rituximab (Mabthera) for ... Leeds Today,
Rituxan® as Maintenance Therapy Reduces Relapses in Non-Hodgkin ... -- Oct 28, 2005
III clinical trial indicate that maintenance therapy with Rituxan® (rituximab) improves progression ... Hodgkin’s lymphoma (NHL) is a form of cancer that begins ... Cancer Consultants (press release),
FDA and Biogen Idec Issue Drug Safety Alert Concerning Fatal ... -- Oct 30, 2005
REACTIONS sections of the Prescribing Information for the cancer drug Zevalin. ... Similar events have been associated with Rituxan (rituximab), a component of the ... Newsinferno.com,
Millennium Announces Clinical Updates at Analyst Day Meeting -- Nov 2, 2005
The trial compared rituximab alone and in combination with VELCADE ... Non-Small Cell Lung Cancer Dr. Tepper presented interim survival data in non-small cell lung ... PR Newswire (press release),
Millennium Announces Clinical Updates at Analyst Day Meeting -- Nov 2, 2005
The trial compared rituximab alone and in combination with VELCADE. ... Dr. Tepper presented interim survival data in non-small cell lung cancer from a phase II ... Yahoo! News (press release)
Phase III MabThera maintenance trial in lymphoma shows positive ... -- Oct 30, 2005
...and Treatment of Cancer (EORTC) that a phase III study[1] in relapsed indolent non-Hodgkin's lymphoma (NHL) evaluating the use of MabThera (rituximab) as ... Medical News Today (press release),
Biotech Has October Blues -- Nov 1, 2005
Accentia's Biovaxid autologous cancer vaccine is in Phase III testing to ... License Application (sBLA) submitted by them for Rituxan (Rituximab) for patients with ... PR Newswire (press release),
New Treatments Improve Survival of Patients with Follicular ... -- Nov 3, 2005
CHOP followed by rituximab versus CHOP followed by 131I-tositumomab radioimmunotherapy, the Lymphoma Committees of Southwest Oncology Group and the Cancer and ... Cancerpage.com,
New treatments improve lymphoma survival -- Nov 2, 2005
...improved overall survival of patients with a blood cancer called follicular ... interferon; and CHOP followed by monoclonal antibody therapy with rituximab or 131I ... Reuters
FDA Grants Priority Review for Rituxan(R) Supplemental Biologics ... -- Oct 25, 2005
License Application (sBLA) submitted by the companies for Rituxan® (Rituximab) in previously ... According to the American Cancer Society, more than 56,000 men and ... Yahoo! News (press release)
Roche and Epitomics enter rabbit MAbs agreement -- Oct 19, 2005
...discovery and development of monoclonal antibodies to treat cancer and other ... market leaders include Roche/Genentech's Rituxan/MabThera (rituximab) and Johnson ... in-PharmaTechnologist,
|
|
|
|
More information on
Rituximab from the National Cancer Institute
Biological therapy is a type of treatment that works with your immune system. It can help fight cancer or help control side effects (how your body reacts to the drugs you are taking) from other cancer treatments like chemotherapy.
What is the difference between biological therapy and chemotherapy?
Biological therapy and chemotherapy are both treatments that fight cancer. While they may seem alike, they work in different ways. Biological therapy helps your immune system fight cancer. Chemotherapy attacks the cancer cells directly.
How does biological therapy fight cancer?
Doctors are not sure how biological therapy helps your immune system fight cancer. But they think it may: - Stop or slow the growth of cancer cells.
- Make it easier for your immune system to destroy, or get rid of, cancer cells.
- Keep cancer from spreading to other parts of your body.
More from the National Cancer Institute
|
|
